DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma

INTRODUCTION: Single-agent belantamab mafodotin (belamaf; BLENREP) demonstrated deep and durable responses in patients with relapsed/refractory multiple myeloma and ≥ 3 prior lines of therapy, including an immunomodulatory agent, proteasome inhibitor, and anti-CD38 antibody (DREAMM-2; NCT03525678)....

Descripción completa

Detalles Bibliográficos
Autores principales: Prawitz, Thibaud, Popat, Rakesh, Suvannasankha, Attaya, Sarri, Grammati, Hughes, Rachel, Wang, Feng, Hogea, Cosmina, Ferrante, Shannon Allen, Gorsh, Boris, Willson, Jenny, Kapetanakis, Venediktos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523001/
https://www.ncbi.nlm.nih.gov/pubmed/34561812
http://dx.doi.org/10.1007/s12325-021-01884-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8523001/
https://www.ncbi.nlm.nih.gov/pubmed/34561812
http://dx.doi.org/10.1007/s12325-021-01884-7

Ejemplares similares